Share Price and Basic Stock Data
Last Updated: February 13, 2026, 8:29 pm
| PEG Ratio | 0.18 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Brooks Laboratories Ltd operates in the pharmaceuticals sector, where it reported a market capitalization of ₹216 Cr and a current share price of ₹74.2. The company’s revenue trajectory has shown fluctuations over the past few quarters. Sales stood at ₹18.08 Cr in September 2022, declined to ₹12.61 Cr by March 2023, and then rebounded to ₹24.32 Cr in September 2023. For the trailing twelve months (TTM), sales reached ₹93 Cr, indicating a recovery phase. However, the overall sales figures for FY 2023 were lower at ₹63 Cr compared to ₹91 Cr in FY 2022. This decline reflects the challenges faced by the company, though the subsequent recovery hints at potential operational improvements. The quarterly sales for December 2023 were ₹21.75 Cr, showing a consistent upward trend that could signal renewed demand and operational stabilization.
Profitability and Efficiency Metrics
Profitability metrics for Brooks Laboratories Ltd indicate significant challenges, with the operating profit margin (OPM) fluctuating drastically. The OPM recorded in September 2022 was a negative 51%, and the company continued to experience negative margins until September 2023, when it stood at negative 4.52%. The negative operating profit persisted through the fiscal year, with an OPM of negative 10% for FY 2025. Despite these challenges, the company recorded a net profit of ₹14 Cr in its latest reporting period, showcasing a turnaround after several quarters of losses. However, the return on equity (ROE) of 12.2% and return on capital employed (ROCE) of 9.93% remain modest compared to industry standards, which typically expect higher returns. The interest coverage ratio (ICR) at 5.66x suggests that Brooks Laboratories has adequate earnings to cover its interest obligations, indicating some degree of financial stability.
Balance Sheet Strength and Financial Ratios
Brooks Laboratories’ balance sheet reveals a conservative financial structure, with total borrowings at ₹8 Cr against reserves of ₹86 Cr. The current ratio of 1.48 indicates sufficient liquidity to cover short-term obligations, while a quick ratio of 1.08 supports this liquidity position. The company’s total liabilities stood at ₹140 Cr, with fixed assets declining to ₹13 Cr, pointing to a potential need for reinvestment in infrastructure. The price-to-book value ratio (P/BV) is reported at 3.23x, which suggests the stock may be overvalued compared to its book value of ₹33.30 per share. The debt-to-equity ratio remains low at 0.06, reflecting a prudent approach to leveraging. However, the overall financial health is under pressure, as evidenced by a decline in the asset turnover ratio to 0.77%, suggesting inefficiencies in generating revenue from assets.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Brooks Laboratories Ltd indicates a significant concentration of ownership, with promoters holding 52.62% of the company shares. This level of promoter ownership can be perceived as a strength, reflecting confidence in the company’s direction. However, foreign institutional investors (FIIs) hold a mere 0.01%, which may reflect a lack of international investor confidence in the company. Domestic institutional investors (DIIs) have increased their stake to 10.38%, indicating some positive sentiment from local institutional players. The public holding stands at 37%, with a total of 10,078 shareholders, suggesting a relatively stable investor base. The gradual decline in promoter shareholding from 66.41% in December 2022 to the current level may raise concerns about long-term commitment and could affect market perceptions.
Outlook, Risks, and Final Insight
The outlook for Brooks Laboratories Ltd appears cautiously optimistic due to the recent recovery in sales and the potential stabilization of operations. However, the company faces significant risks, including ongoing profitability challenges and dependency on a limited product portfolio. The fluctuating OPM and negative earnings in recent years highlight the need for operational improvements and strategic initiatives to enhance margins. Potential growth could arise from increased demand for pharmaceuticals, but competition in the sector remains fierce. Investors should closely monitor the company’s ability to maintain its sales momentum and improve profitability metrics. Additionally, the reliance on promoter ownership may create volatility in stock performance if there are changes in management or strategic direction. Overall, Brooks Laboratories is at a critical juncture; successful navigation of these challenges could lead to enhanced shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 143/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,391 Cr. | 312 | 479/192 | 71.0 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 201 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,957.38 Cr | 1,098.00 | 53.12 | 201.93 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.08 | 15.30 | 12.61 | 15.70 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 |
| Expenses | 27.30 | 23.85 | 16.31 | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 22.02 | 24.58 | 22.38 | 20.93 |
| Operating Profit | -9.22 | -8.55 | -3.70 | -3.91 | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -1.50 | -1.26 | 3.13 | 2.52 |
| OPM % | -51.00% | -55.88% | -29.34% | -24.90% | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -7.31% | -5.40% | 12.27% | 10.75% |
| Other Income | 0.40 | 0.45 | 0.03 | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.03 | 0.62 | 7.15 | 6.13 |
| Interest | 0.63 | 0.75 | 0.18 | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.30 | 0.28 |
| Depreciation | 2.28 | 2.33 | 0.44 | 0.44 | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 |
| Profit before tax | -11.73 | -11.18 | -4.29 | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 |
| Tax % | -32.82% | -15.21% | 0.00% | 0.00% | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.00% | 13.95% | 0.00% | 0.00% |
| Net Profit | -7.87 | -9.48 | -4.29 | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 |
| EPS in Rs | -1.79 | -1.92 | -1.64 | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.50 | 3.25 | 2.71 |
Last Updated: January 2, 2026, 4:29 am
Below is a detailed analysis of the quarterly data for Brooks Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 23.45 Cr.. The value appears to be declining and may need further review. It has decreased from 25.51 Cr. (Jun 2025) to 23.45 Cr., marking a decrease of 2.06 Cr..
- For Expenses, as of Sep 2025, the value is 20.93 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.38 Cr. (Jun 2025) to 20.93 Cr., marking a decrease of 1.45 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.52 Cr.. The value appears to be declining and may need further review. It has decreased from 3.13 Cr. (Jun 2025) to 2.52 Cr., marking a decrease of 0.61 Cr..
- For OPM %, as of Sep 2025, the value is 10.75%. The value appears to be declining and may need further review. It has decreased from 12.27% (Jun 2025) to 10.75%, marking a decrease of 1.52%.
- For Other Income, as of Sep 2025, the value is 6.13 Cr.. The value appears to be declining and may need further review. It has decreased from 7.15 Cr. (Jun 2025) to 6.13 Cr., marking a decrease of 1.02 Cr..
- For Interest, as of Sep 2025, the value is 0.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.30 Cr. (Jun 2025) to 0.28 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.39 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.39 Cr..
- For Profit before tax, as of Sep 2025, the value is 7.98 Cr.. The value appears to be declining and may need further review. It has decreased from 9.59 Cr. (Jun 2025) to 7.98 Cr., marking a decrease of 1.61 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 7.98 Cr.. The value appears to be declining and may need further review. It has decreased from 9.58 Cr. (Jun 2025) to 7.98 Cr., marking a decrease of 1.60 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.71. The value appears to be declining and may need further review. It has decreased from 3.25 (Jun 2025) to 2.71, marking a decrease of 0.54.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:32 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 83 | 93 |
| Expenses | 77 | 105 | 93 | 97 | 91 | 90 |
| Operating Profit | 1 | -14 | -30 | -18 | -8 | 3 |
| OPM % | 1% | -16% | -47% | -22% | -10% | 3% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 14 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 |
| Profit before tax | -9 | -24 | -38 | -20 | -10 | 14 |
| Tax % | 115% | -19% | -19% | 0% | 2% | |
| Net Profit | -19 | -19 | -31 | -20 | -10 | 14 |
| EPS in Rs | -7.40 | -4.31 | -7.97 | -7.46 | -3.38 | 4.65 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -63.16% | 35.48% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -63.16% | 98.64% | 14.52% |
Brooks Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -3% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| TTM: | 112% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 3% |
| 1 Year: | 18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -22% |
| Last Year: | -12% |
Last Updated: September 5, 2025, 1:25 am
Balance Sheet
Last Updated: December 4, 2025, 1:04 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 86 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 8 |
| Other Liabilities | 52 | 83 | 29 | 19 | 18 | 16 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 140 |
| Fixed Assets | 108 | 110 | 15 | 14 | 14 | 13 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 86 |
| Other Assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 140 |
Below is a detailed analysis of the balance sheet data for Brooks Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 29.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.00 Cr..
- For Reserves, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 69.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing). It has decreased from 18.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 140.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 124.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 16.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 74.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 12.00 Cr..
- For Other Assets, as of Sep 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 40.00 Cr., marking an increase of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 124.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 16.00 Cr..
Notably, the Reserves (86.00 Cr.) exceed the Borrowings (8.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | -30.00 | -39.00 | -37.00 | -24.00 | -16.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 64.73 | 70.69 | 73.64 | 74.94 | 88.38 |
| Inventory Days | 177.86 | 156.51 | 79.89 | 60.49 | 62.10 |
| Days Payable | 233.26 | 159.24 | 165.21 | 97.25 | 91.94 |
| Cash Conversion Cycle | 9.34 | 67.96 | -11.69 | 38.18 | 58.54 |
| Working Capital Days | -84.81 | 33.99 | -37.48 | 33.57 | 43.28 |
| ROCE % | -15.50% | -30.45% | -24.70% | -9.90% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Business Cycle Fund | 528,937 | 0.84 | 6.69 | 528,937 | 2025-04-22 17:25:39 | 0% |
| Quant Healthcare Fund | 276,708 | 1.99 | 3.5 | 276,708 | 2025-04-22 17:25:39 | 0% |
| Quant Small Cap Fund | 187,346 | 0.02 | 2.37 | 187,346 | 2025-04-22 17:25:39 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.72 | -7.65 | -12.57 | -7.82 | -7.84 |
| Diluted EPS (Rs.) | -3.72 | -7.65 | -12.57 | -7.82 | -7.84 |
| Cash EPS (Rs.) | 1.57 | 1.26 | -8.39 | -4.84 | -4.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.30 | 24.99 | 29.94 | 54.37 | 32.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.30 | 24.99 | 29.94 | 54.37 | 32.04 |
| Revenue From Operations / Share (Rs.) | 28.03 | 30.28 | 25.59 | 36.87 | 31.27 |
| PBDIT / Share (Rs.) | 1.98 | 1.59 | -10.61 | -5.44 | 0.50 |
| PBIT / Share (Rs.) | 1.43 | 0.91 | -13.46 | -8.42 | -2.38 |
| PBT / Share (Rs.) | 1.08 | 0.59 | -14.20 | -9.67 | -3.64 |
| Net Profit / Share (Rs.) | 1.02 | 0.58 | -11.23 | -7.82 | -7.84 |
| NP After MI And SOA / Share (Rs.) | -3.38 | -7.46 | -8.46 | -6.55 | -7.84 |
| PBDIT Margin (%) | 7.05 | 5.24 | -41.47 | -14.76 | 1.62 |
| PBIT Margin (%) | 5.11 | 3.01 | -52.59 | -22.83 | -7.62 |
| PBT Margin (%) | 3.86 | 1.95 | -55.48 | -26.23 | -11.63 |
| Net Profit Margin (%) | 3.65 | 1.92 | -43.89 | -21.20 | -25.07 |
| NP After MI And SOA Margin (%) | -12.07 | -24.64 | -33.06 | -17.77 | -25.08 |
| Return on Networth / Equity (%) | -10.15 | -29.87 | -28.26 | -25.67 | -24.47 |
| Return on Capital Employeed (%) | 4.18 | 3.56 | -43.41 | -14.14 | -5.98 |
| Return On Assets (%) | -8.05 | -21.66 | -19.06 | -8.26 | -11.95 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.14 | 0.18 |
| Total Debt / Equity (X) | 0.06 | 0.07 | 0.07 | 0.38 | 0.35 |
| Asset Turnover Ratio (%) | 0.77 | 0.79 | 0.41 | 0.57 | 0.00 |
| Current Ratio (X) | 1.48 | 1.35 | 0.83 | 1.25 | 0.78 |
| Quick Ratio (X) | 1.08 | 0.93 | 0.49 | 0.68 | 0.41 |
| Inventory Turnover Ratio (X) | 8.78 | 4.28 | 2.14 | 2.31 | 0.00 |
| Interest Coverage Ratio (X) | 5.66 | 4.94 | -12.01 | -4.34 | 0.40 |
| Interest Coverage Ratio (Post Tax) (X) | 3.93 | 2.81 | -11.87 | -5.24 | -5.25 |
| Enterprise Value (Cr.) | 322.19 | 247.92 | 159.23 | 271.01 | 179.90 |
| EV / Net Operating Revenue (X) | 3.90 | 3.12 | 2.52 | 2.98 | 2.33 |
| EV / EBITDA (X) | 55.34 | 59.41 | -6.07 | -20.15 | 143.19 |
| MarketCap / Net Operating Revenue (X) | 3.84 | 3.06 | 2.45 | 1.97 | 1.99 |
| Price / BV (X) | 3.23 | 3.71 | 2.09 | 2.84 | 1.94 |
| Price / Net Operating Revenue (X) | 3.84 | 3.06 | 2.45 | 1.97 | 1.99 |
| EarningsYield | -0.03 | -0.08 | -0.13 | -0.09 | -0.12 |
After reviewing the key financial ratios for Brooks Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.72. This value is below the healthy minimum of 5. It has increased from -7.65 (Mar 24) to -3.72, marking an increase of 3.93.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.72. This value is below the healthy minimum of 5. It has increased from -7.65 (Mar 24) to -3.72, marking an increase of 3.93.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 1.57, marking an increase of 0.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.30. It has increased from 24.99 (Mar 24) to 33.30, marking an increase of 8.31.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.30. It has increased from 24.99 (Mar 24) to 33.30, marking an increase of 8.31.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.03. It has decreased from 30.28 (Mar 24) to 28.03, marking a decrease of 2.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.98. This value is below the healthy minimum of 2. It has increased from 1.59 (Mar 24) to 1.98, marking an increase of 0.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.43, marking an increase of 0.52.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.08. This value is within the healthy range. It has increased from 0.59 (Mar 24) to 1.08, marking an increase of 0.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.02. This value is below the healthy minimum of 2. It has increased from 0.58 (Mar 24) to 1.02, marking an increase of 0.44.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.38. This value is below the healthy minimum of 2. It has increased from -7.46 (Mar 24) to -3.38, marking an increase of 4.08.
- For PBDIT Margin (%), as of Mar 25, the value is 7.05. This value is below the healthy minimum of 10. It has increased from 5.24 (Mar 24) to 7.05, marking an increase of 1.81.
- For PBIT Margin (%), as of Mar 25, the value is 5.11. This value is below the healthy minimum of 10. It has increased from 3.01 (Mar 24) to 5.11, marking an increase of 2.10.
- For PBT Margin (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.86, marking an increase of 1.91.
- For Net Profit Margin (%), as of Mar 25, the value is 3.65. This value is below the healthy minimum of 5. It has increased from 1.92 (Mar 24) to 3.65, marking an increase of 1.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -12.07. This value is below the healthy minimum of 8. It has increased from -24.64 (Mar 24) to -12.07, marking an increase of 12.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is -10.15. This value is below the healthy minimum of 15. It has increased from -29.87 (Mar 24) to -10.15, marking an increase of 19.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 10. It has increased from 3.56 (Mar 24) to 4.18, marking an increase of 0.62.
- For Return On Assets (%), as of Mar 25, the value is -8.05. This value is below the healthy minimum of 5. It has increased from -21.66 (Mar 24) to -8.05, marking an increase of 13.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has decreased from 0.79 (Mar 24) to 0.77, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has increased from 1.35 (Mar 24) to 1.48, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 1.08. This value is within the healthy range. It has increased from 0.93 (Mar 24) to 1.08, marking an increase of 0.15.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.78. This value exceeds the healthy maximum of 8. It has increased from 4.28 (Mar 24) to 8.78, marking an increase of 4.50.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.66. This value is within the healthy range. It has increased from 4.94 (Mar 24) to 5.66, marking an increase of 0.72.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.93. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 3.93, marking an increase of 1.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 322.19. It has increased from 247.92 (Mar 24) to 322.19, marking an increase of 74.27.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.90. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 3.90, marking an increase of 0.78.
- For EV / EBITDA (X), as of Mar 25, the value is 55.34. This value exceeds the healthy maximum of 15. It has decreased from 59.41 (Mar 24) to 55.34, marking a decrease of 4.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 3.84, marking an increase of 0.78.
- For Price / BV (X), as of Mar 25, the value is 3.23. This value exceeds the healthy maximum of 3. It has decreased from 3.71 (Mar 24) to 3.23, marking a decrease of 0.48.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 3.84, marking an increase of 0.78.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.08 (Mar 24) to -0.03, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Brooks Laboratories Ltd:
- Net Profit Margin: 3.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.18% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -10.15% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.08
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 10.3 (Industry average Stock P/E: 53.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.65%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Kishanpura,. Solan District Himachal Pradesh 174101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhushan Singh Rana | Whole Time Director |
| Mr. Jitendra Pratap Singh | Whole Time Director |
| Mr. Durga Shankar Maity | Whole Time Director |
| Mr. Manav Mahajan | Independent Director |
| Mr. Lalit Mahajan | Independent Director |
| Dr. Usha Singh | Independent Director |
FAQ
What is the intrinsic value of Brooks Laboratories Ltd?
Brooks Laboratories Ltd's intrinsic value (as of 14 February 2026) is ₹63.82 which is 15.80% lower the current market price of ₹75.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹223 Cr. market cap, FY2025-2026 high/low of ₹166/58.4, reserves of ₹86 Cr, and liabilities of ₹140 Cr.
What is the Market Cap of Brooks Laboratories Ltd?
The Market Cap of Brooks Laboratories Ltd is 223 Cr..
What is the current Stock Price of Brooks Laboratories Ltd as on 14 February 2026?
The current stock price of Brooks Laboratories Ltd as on 14 February 2026 is ₹75.8.
What is the High / Low of Brooks Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Brooks Laboratories Ltd stocks is ₹166/58.4.
What is the Stock P/E of Brooks Laboratories Ltd?
The Stock P/E of Brooks Laboratories Ltd is 10.3.
What is the Book Value of Brooks Laboratories Ltd?
The Book Value of Brooks Laboratories Ltd is 39.3.
What is the Dividend Yield of Brooks Laboratories Ltd?
The Dividend Yield of Brooks Laboratories Ltd is 0.00 %.
What is the ROCE of Brooks Laboratories Ltd?
The ROCE of Brooks Laboratories Ltd is 9.93 %.
What is the ROE of Brooks Laboratories Ltd?
The ROE of Brooks Laboratories Ltd is 12.2 %.
What is the Face Value of Brooks Laboratories Ltd?
The Face Value of Brooks Laboratories Ltd is 10.0.